Munder Home
|  Home  |   Institutional  |  Mutual Funds  |   Investment Professionals  |   Retirement Services  |

800.468.6337





















Seeks long-term capital appreciation through investments primarily in health care companies, which are companies for which at least 50% of sales, earnings or assets arise from or are dedicated to health or medical-related activities.  
Class A B^ C R
Ticker MFHAX MFHBX MFHCX MHCRX
CUSIP 626120703 626120802 626120885 626127203
Fund Code 282 382 482 882
Inception Date 02/14/97 01/31/97 01/13/97 07/29/04
Minimum Initial Investment: $2,500; $50 subsequent/automatic
Learn more
^Open to limited investors only

Equity fund style boxes provide a wealth of information in just a glance. These easy-to-understand visual references summarize a fund's investment strategy. More here

MORE FUND INFORMATION
Download the Fact Sheet | Prospectus | Annual Report | Commentary
     
 
 
Healthcare
Daily NAV's as of 07/30/10
Class A Class B^ Class C Class R
NAV 21.83 19.72 19.70 21.49
Chg. $ 0.16 0.14 0.14 0.15
Chg. % 0.74 0.72 0.72 0.70
POP 23.10 19.72 19.70 21.49
YTD Return % -9.04 -9.46 -9.47 -9.17
52 Wk High
Date
25.38
03/23/10
23.00
03/23/10
22.97
03/23/10
25.01
03/23/10
52 Wk Low
Date
21.23
08/06/09
19.32
08/06/09
19.30
08/06/09
20.96
08/06/09
Download Historical NAV/POP

     
Healthcare Fund Total Returns (%) as of 06/30/10    Risks
- - - - - Cumulative - - - - -
- - - - - Annualized - - - - -
Class 1 month 3 month YTD 1 year 3 year 5 year 10 year SI Inception Date
A With load -8.32 -17.07 -14.09 0.18 -8.31 -2.81 -2.88 4.88 02/14/97
A Without load -2.98 -12.23 -9.08 6.03 -6.56 -1.71 -2.33 5.32 02/14/97
B^ With load -7.85 -16.73 -13.94 0.28 -8.20 -2.83 -2.91 5.04 01/31/97
B^ Without load -3.00 -12.35 -9.41 5.28 -7.27 -2.44 -2.91 5.04 01/31/97
C With load -3.97 -13.24 -10.33 4.23 -7.26 -2.44 -3.06 5.15 01/13/97
C Without load -3.00 -12.36 -9.42 5.23 -7.26 -2.44 -3.06 5.15 01/13/97
R Without load -2.98 -12.25 -9.17 5.76 -6.81 -1.96 N/A 0.70 07/29/04
 

Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal will fluctuate so that an investor's shares, when redeemed may be worth more or less than the original cost.

The recent growth rate in the stock market has helped produce short-term returns for some asset classes that are not typical and may not continue in the future. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

As identified in the current Fund prospectus, the Class A, B, C and R shares gross expense ratios for the fiscal year ended June 30, 2009 were 2.28%, 3.03%, 3.03% and 2.53%, respectively. The Fund publishes Semi-Annual and Annual Reports each February and August, which contain updated expense ratio information. In periods of market volatility, Fund assets may decline significantly, causing a Fund’s gross expense ratio to become higher than the gross expense ratio shown in the current prospectus. The Advisor limited certain expenses of Class A, B and C shares of the Fund during the 1997-2002 calendar years. The Advisor also made a voluntary capital contribution to the Fund during the 2005 calendar year. In addition, the Fund’s former sub-advisor made a capital contribution to the Fund during the 2004 calendar year. Total returns would have been lower if Munder Capital Management or the former sub-advisor had not limited expenses or made a capital contributions during those periods.

Class A Shares have a maximum sales charge of 5.5% on Equity Funds (excluding the Index 500 Fund), 2.5% on the Index 500 Fund, 4% on the Bond Fund, and 2% on the Tax-Free Short & Intermediate Bond Fund.Class B Shares of all Funds except the Index 500 Fund have a Contingent Deferred Sales Charge (CDSC) on redemptions made within six years of purchase as follows: Year 1 = 5.0%, Year 2 = 4.0%, Year 3 = 3.0%, Year 4 = 3.0%, Year 5 = 2.0%, Year 6 = 1.0%. Class B Shares of the Index 500 Fund have a CDSC on redemptions made within six years of purchase as follows: Year 1 = 3.0%, Year 2 = 2.50%, Year 3 = 2.0%, Year 4 = 1.5%, Year 5 = 1.0%, Year 6 = 0.5%.Class C Shares of all Funds have a 1.0% Contingent Deferred Sales Charge (CDSC) on redemptions made within one year of purchase. Class R Shares are not subject to sales charges. Class R Shares are only available for purchase by limited types of investors, as outlined in the Fund’s prospectus.

Different sales charges affect performance and yields.

 

An investor should consider the Fund's investment objectives, risks, and charges and expenses carefully before sending money. The prospectus and summary prospectus contain this and other important information about the investment company. To obtain a prospectus and summary prospectus, please click here. Please read the prospectus and summary prospectuses carefully before investing.

RISKS 

The Fund concentrates its investments in health care-related securities, particularly within the pharmaceuticals industries, and is therefore subject to higher market risk and price volatility than funds with more broadly diversified investments. In addition, the Fund may invest up to 25% of its assets in foreign securities, which involve additional risks due to currency fluctuations, economic and political conditions, and differences in financial reporting standards.

 

1A weighted median market cap is calculated by arranging companies in a portfolio, along with their weight (the percentage of market value that each company represents in the portfolio as a whole), from the highest to lowest capitalization.  The weights are then summed until 50% of the portfolio's weighted market cap is reached. The purpose of the weighted median is to reduce the influence of outliers on the market cap calculation. 

 

The portfolio holding information provided should not be considered as a recommendation to purchase or sell a particular security. There is no assurance that the securities mentioned remain in the Fund's portfolio or that securities sold have not been repurchased.

Country classifications are based on the country in which the issuer is headquartered and do not include exposure through holdings of foreign currencies, which are included in "Cash & Equivalents". Fund/ETF holdings are classified based on the country exposure represented by the Fund/ETF, and may be classified as "Multi-Country." The percentages shown represent the breakdown of investments and are not based on net assets.

*Total net asset figures do not reflect adjustments, if any, made for financial reporting purposes. Percentages shown for Asset Allocation, Top Ten Holdings, Industry Diversification and Country Diversification represent the breakdown of investments and are not based on net assets. Portfolio holdings will change and should not be considered purchase recommendations. Top holdings do not reflect cash, money market instruments or options/futures contracts holdings.

Fund shares are not guaranteed or insured by any bank, the FDIC or any government agency, and may lose value.  

The percentages shown are rounded to the nearest tenth of one percent.

N/A - Fund class was not in operation for that time period.

^Open to limited investors only. 
 



Munder Funds distributed by Funds Distributor, LLC.

E-mail us at feedback@munder.com
Please read the Terms of Use and Privacy Policy
Munder®, Munder Capital®, Munder Capital Management®, and The Munder Funds® are
registered trademarks of Munder Capital Management®.

  ©Copyright 2010 Munder Capital Management. All Rights Reserved.
 
 
Healthcare
Quarterly Commentary as of June 30, 2010
previous commentary Print or Download
Reflecting the negative tone of the stock market, both the Munder Healthcare Fund and its S&P North American Health Care Sector™ benchmark posted a double-digit negative return for the second quarter of 2010, with the Fund lagging its S&P benchmark. The timing of the passage of health care legislation gave management teams a very narrow window to digest the provisions of the bill before their earnings releases. Many companies, especially pharmaceutical manufacturers and profitable biotech companies, were caught off guard by the lower drug prices they will receive from Medicaid, which resulted in reduced growth estimates.

The Fund benefited from being underweighted in managed care stocks, especially WellPoint, Inc. (1.6% of the Fund) and Aetna, Inc. (0.7%). In addition, there were a number of stocks that had a positive impact on relative performance. AmerisourceBergen Corp. (1.8%) posted continued strong earnings based on new business wins and increased generic utilization. Watson Pharmaceuticals, Inc. (1.5%) also posted strong earnings and its Arrow acquisition remained on track. Ev3, Inc. (0.7%) announced that it was being acquired by Covidien Ltd. Vivus, Inc. (0.1%) reported some positive phase three data on a key drug development.

Relative weakness was more or less company specific. In addition to the lower drug prices that it will receive from Medicaid, Gilead Sciences, Inc. (2.8%) suffered from concerns over decelerating growth as its key HIV drugs mature. Kinetic Concepts, Inc. (1.2%) declined on fears that its key wound therapy business was not stabilizing. Despite strong earnings, Teva Pharmaceutical Industries Ltd. (1.3%), Medco Health Solutions, Inc. (2.4%) and McKesson Corp. (1.9%) all lagged the benchmark on general fears over the impact of health reform.

During the quarter, the Fund’s industry weights were changed as a result of the analysis of reported earnings. Specifically, branded pharmaceutical exposure was reduced due to the impact of health reform and the expectation of reduced earnings over the next few years due to increased Medicaid discounts and a new excise tax. We continue to favor generic drug companies within the pharmaceutical sector. An overweight in health care providers and services, which largely reflected increased positions in hospitals and drug distributors, was continued. The Fund remained underweighted in equipment and supply companies as we continued to believe that the potential for relative earnings growth in this segment is not as powerful as in other health care industries at the present time, especially in cardiac and orthopedic industries.

 

Past performance does not guarantee future results. The Fund's investment objectives, risks, charges and expenses must be considered carefully before investing.  The prospectus and summary prospectus contain this and other important information about the Fund. To obtain a prospectus and summary prospectus, click here.  Read the prospectus and summary prospectuses carefully before investing.

RISKS: The Fund concentrates its investments in health care-related securities, particularly within the pharmaceuticals industries, and is therefore subject to higher market risk and price volatility than funds with more broadly diversified investments. Investors should also note that the Fund may invest up to 25% of its assets in foreign securities, which involve additional risks due to currency fluctuations, economic and political conditions, and differences in financial reporting standards.

Fund holdings mentioned in the Quarterly Commentary are as of 5.31.10 and the percentages shown are based on net assets as of that date. Fund holdings are subject to change and should not be considered purchase recommendations. There is no assurance that the securities mentioned remain in the Fund’s portfolio or that securities sold have not been repurchased

The S&P North American Health Care Sector IndexTM  is a modified capitalization-weighted index designed to measure the performance of U.S. publicly-traded securities in the health care sector. The S&P 500® Index is a widely recognized capitalization-weighted index that measures the performance of the large-capitalization sector of the U.S. stock market. You cannot invest directly in an index, securities in the Fund will not match those in the index, and performance of the Fund will differ. Although reinvestment of dividend and interest payments is assumed, no expenses are netted against an index’s returns.

Munder Funds are distributed by Funds Distributor, LLC 07/10


 
Investment Team
Michael P Gura, CFA
 
Michael P. Gura, CFA
Senior Portfolio Manager
BBA in Finance from Walsh College
MS in Finance with Distinction from Walsh College
Started with Comerica Bank in 1986. Joined Munder Capital in 1995 as a result of the merger with Comerica and its investment subsidiaries.
Years of Experience:22
Focus:Member of the portfolio management teams managing Munder Capital's Large-Capitalization Growth and Multi-Capitalization Growth investment strategies and their associated mutual funds as well as the Large-Cap Growth and Multi-Cap Growth segments of the Munder Asset Allocation Fund - Balanced. Also manages Munder Capital’s Healthcare equity strategy, including the Munder Healthcare Fund.

Munder Funds distributed by Funds Distributor, LLC.

 

Healthcare
Portfolio Data as of 06/30/2010
Total Net Assets* $47,170,237
Number of Holdings 78
Weighted Average Market Cap $387,527 MM
Weighted Median Market Cap1 $23,421 MM
P/E Ratio - Last 12 Mos 12.67
Earnings Growth - Last 5 Yrs 11.4%
Earnings Growth - Last 12 Mos. 12.0%
Beta 1.00
Turnover - as of 6/30/2010 88.9%

Asset Allocation as of 06/30/2010
Cash & Equivalents 0.4 %
Equity 99.6 %
Total 100.0 %
 
 
There were no buy transactions for the month of June 2010
 
There were no sell transactions for the month of June 2010
 
 
Top Holdings as of 06/30/2010 Holdings Detail
Symbol Company Name
ABT Abbott Laboratories
AMGN Amgen, Inc.
BMY Bristol-Myers Squibb Co.
CELG Celgene Corp.
LLY Eli Lilly and Company
ESRX Express Scripts, Inc.
JNJ Johnson & Johnson
MDT Medtronic, Inc.
MRK Merck & Co., Inc.
PFE Pfizer, Inc.
  Total Percentage of Top Holdings: 39.9
  Link to All Holdings as of 6/30/2010
  Historical All Holdings
 
Industry Diversification as of 06/30/2010
Industry % of Holdings
Pharmaceuticals 29.7
Health Care Equipment 17.7
Biotechnology 16.1
Health Care Services 8.3
Managed Health Care 7.1
Unassigned 7.0
Health Care Distributors 4.3
Health Care Facilities 4.0
Life Sciences Tools & Services 3.6
Health Care Technology 0.5
Medical Services 0.5
Health Care Supplies 0.5
Cash & Equivalents 0.4
Unclassified 0.2
Health Care 0.1
Total 100.0
 
Country of Headquarters as of 06/30/2010
Country % of Holdings
Ireland 1.0
Israel 0.5
Switzerland 0.9
United States 97.2
Cash & Equivalents 0.4
Total 100.0
 

An investor should consider the Fund's investment objectives, risks, and charges and expenses carefully before sending money. The prospectus and summary prospectus contain this and other important information about the investment company. To obtain a prospectus and summary prospectus, please click here. Please read the prospectus and summary prospectuses carefully before investing.

RISKS 

The Fund concentrates its investments in health care-related securities, particularly within the pharmaceuticals industries, and is therefore subject to higher market risk and price volatility than funds with more broadly diversified investments. In addition, the Fund may invest up to 25% of its assets in foreign securities, which involve additional risks due to currency fluctuations, economic and political conditions, and differences in financial reporting standards.

 

1A weighted median market cap is calculated by arranging companies in a portfolio, along with their weight (the percentage of market value that each company represents in the portfolio as a whole), from the highest to lowest capitalization.  The weights are then summed until 50% of the portfolio's weighted market cap is reached. The purpose of the weighted median is to reduce the influence of outliers on the market cap calculation. 

 

The portfolio holding information provided should not be considered as a recommendation to purchase or sell a particular security. There is no assurance that the securities mentioned remain in the Fund's portfolio or that securities sold have not been repurchased.

Country classifications are based on the country in which the issuer is headquartered and do not include exposure through holdings of foreign currencies, which are included in "Cash & Equivalents". Fund/ETF holdings are classified based on the country exposure represented by the Fund/ETF, and may be classified as "Multi-Country." The percentages shown represent the breakdown of investments and are not based on net assets.

*Total net asset figures do not reflect adjustments, if any, made for financial reporting purposes. Percentages shown for Asset Allocation, Top Ten Holdings, Industry Diversification and Country Diversification represent the breakdown of investments and are not based on net assets. Portfolio holdings will change and should not be considered purchase recommendations. Top holdings do not reflect cash, money market instruments or options/futures contracts holdings.

Fund shares are not guaranteed or insured by any bank, the FDIC or any government agency, and may lose value.  

The percentages shown are rounded to the nearest tenth of one percent.

N/A - Fund class was not in operation for that time period.

^Open to limited investors only. 
 



Munder Funds distributed by Funds Distributor, LLC.

E-mail us at feedback@munder.com
Please read the Terms of Use and Privacy Policy
Munder®, Munder Capital®, Munder Capital Management®, and The Munder Funds® are
registered trademarks of Munder Capital Management®.

  ©Copyright 2010 Munder Capital Management. All Rights Reserved.